Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Oct;36(10):2334–2337. doi: 10.1128/aac.36.10.2334

Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model.

K Vance-Bryan 1, T A Larson 1, J C Rotschafer 1, J P Toscano 1
PMCID: PMC245499  PMID: 1332596

Abstract

The purpose of this study was to develop a pharmacodynamic model to describe the dependency of the rate of Staphylococcus aureus killing upon the concentration of daptomycin. A range of free (unbound) daptomycin concentrations ranging from 0.12 to 27 times the MIC were simulated in the peripheral compartment of a two-compartment pharmacokinetic model. Log-linear regression of free daptomycin concentrations versus growth or kill rate constants showed a significant correlation (r = -0.90; P less than 0.001). A Lineweaver-Burk plot of the reciprocal transformation of these data yielded a poor fit (r = -0.38; P greater than 0.05). When a Lineweaver-Burk-type regression analysis was performed on the reciprocal of the change in the rate constant rather than the rate constant itself, the result demonstrated good correlation (r = 0.90; P less than 0.0001). The observations were also well described by a sigmoidal maximum plateau pharmacologic effect model, in which the pharmacologic effect of daptomycin is a reduction in the bacterial exponential growth rate constant from the baseline in the absence of antibiotic to a lower (positive) growth or (negative) death rate constant observed in the presence of antibiotic. These data confirm that daptomycin exhibits concentration-dependent killing over a wide range of free daptomycin concentrations relative to the MIC and suggest that this is a saturable process similar to the Michaelis-Menten pharmacokinetic elimination of certain drugs.

Full text

PDF
2334

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ehlert F., Neu H. C. In vitro activity of LY146032 (daptomycin), a new peptolide. Eur J Clin Microbiol. 1987 Feb;6(1):84–90. doi: 10.1007/BF02097208. [DOI] [PubMed] [Google Scholar]
  2. Eliopoulos G. M., Willey S., Reiszner E., Spitzer P. G., Caputo G., Moellering R. C., Jr In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother. 1986 Oct;30(4):532–535. doi: 10.1128/aac.30.4.532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fass R. J., Helsel V. L. In vitro activity of LY146032 against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother. 1986 Nov;30(5):781–784. doi: 10.1128/aac.30.5.781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Flandrois J. P., Fardel G., Carret G. Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus. Antimicrob Agents Chemother. 1988 Apr;32(4):454–457. doi: 10.1128/aac.32.4.454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Garrison M. W., Vance-Bryan K., Larson T. A., Toscano J. P., Rotschafer J. C. Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 1990 Oct;34(10):1925–1931. doi: 10.1128/aac.34.10.1925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Huovinen P., Kotilainen P. In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria. Antimicrob Agents Chemother. 1987 Mar;31(3):455–457. doi: 10.1128/aac.31.3.455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jones R. N., Barry A. L. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrob Agents Chemother. 1987 Apr;31(4):625–629. doi: 10.1128/aac.31.4.625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jorgensen J. H., Maher L. A., Redding J. S. In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria. Eur J Clin Microbiol. 1987 Feb;6(1):91–96. doi: 10.1007/BF02097209. [DOI] [PubMed] [Google Scholar]
  9. Machka K., Braveny I. Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci. Eur J Clin Microbiol. 1987 Feb;6(1):96–99. doi: 10.1007/BF02097210. [DOI] [PubMed] [Google Scholar]
  10. Stratton C. W., Liu C., Ratner H. B., Weeks L. S. Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies. Antimicrob Agents Chemother. 1987 Jul;31(7):1014–1016. doi: 10.1128/aac.31.7.1014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Stratton C. W., Weeks L. S. Effect of human serum on the bactericidal activity of daptomycin and vancomycin against staphylococcal and enterococcal isolates as determined by time-kill kinetic studies. Diagn Microbiol Infect Dis. 1990 May-Jun;13(3):245–252. doi: 10.1016/0732-8893(90)90067-6. [DOI] [PubMed] [Google Scholar]
  12. Van der Auwera P. Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin. Antimicrob Agents Chemother. 1989 Oct;33(10):1783–1790. doi: 10.1128/aac.33.10.1783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Verbist L. In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci. Antimicrob Agents Chemother. 1987 Feb;31(2):340–342. doi: 10.1128/aac.31.2.340. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES